AI Engines For more Details: Perplexity Kagi Labs You
Depression: Paroxetine hydrochloride is primarily prescribed for the treatment of depression. It works by increasing the levels of serotonin, a neurotransmitter, in the brain, which helps improve mood and alleviate depressive symptoms.
Anxiety Disorders: Paroxetine hydrochloride is also used to treat various anxiety disorders, including generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder, and obsessive-compulsive disorder (OCD).
Premenstrual Dysphoric Disorder (PMDD): Paroxetine hydrochloride may be prescribed to manage symptoms of PMDD, a severe form of premenstrual syndrome (PMS), such as mood swings, irritability, and physical symptoms.
Post-Traumatic Stress Disorder (PTSD): Paroxetine hydrochloride is sometimes used off-label to treat symptoms of PTSD, such as intrusive thoughts, flashbacks, nightmares, and hypervigilance.
Other Conditions: Paroxetine hydrochloride may also be prescribed off-label for conditions such as eating disorders, certain types of chronic pain, and menopausal symptoms.
Side Effects: Common side effects of paroxetine hydrochloride may include nausea, drowsiness, dry mouth, constipation, sweating, sexual dysfunction, and weight changes. These side effects are usually mild and may diminish over time. However, some individuals may experience more severe side effects or allergic reactions, such as rash, swelling, or difficulty breathing, which require immediate medical attention.
Withdrawal Symptoms: Discontinuing paroxetine hydrochloride abruptly or too rapidly may lead to withdrawal symptoms, commonly referred to as "discontinuation syndrome." These symptoms may include dizziness, headache, nausea, fatigue, irritability, and flu-like symptoms. It's essential to taper off the medication gradually under the supervision of a healthcare professional to minimize withdrawal effects.
Suicidal Thoughts and Behavior: Like other antidepressants, paroxetine hydrochloride may increase the risk of suicidal thoughts or behaviors, especially in children, adolescents, and young adults. Close monitoring is necessary, particularly when starting the medication or adjusting the dosage.
Serotonin Syndrome: In rare cases, the use of paroxetine hydrochloride may lead to serotonin syndrome, a potentially life-threatening condition characterized by dangerously high levels of serotonin in the brain. Symptoms may include agitation, hallucinations, rapid heartbeat, fever, excessive sweating, shivering, muscle stiffness, tremors, and loss of coordination. Seek immediate medical attention if you experience any of these symptoms.
Drug Interactions: Paroxetine hydrochloride can interact with other medications, including other antidepressants, certain pain medications, migraine drugs, blood thinners, and herbal supplements like St. John's wort. It's crucial to inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.
Pregnancy and Breastfeeding: The use of paroxetine hydrochloride during pregnancy may be associated with an increased risk of certain birth defects and complications, particularly if used during the first trimester. It may also pass into breast milk and potentially affect the nursing infant. If you are pregnant or breastfeeding, discuss the risks and benefits of using paroxetine hydrochloride with your healthcare provider.
Liver and Kidney Function: Paroxetine hydrochloride should be used with caution in individuals with impaired liver or kidney function, as the dosage may need to be adjusted based on the severity of impairment.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0 | 0 | |
| ADHD | 0.6 | 0.1 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.1 | 2 |
| Allergies | 1.4 | 1.5 | -0.07 |
| Allergy to milk products | 0.5 | 0 | 0 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 0.3 | 1.9 | -5.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.8 | 0 |
| Ankylosing spondylitis | 1.5 | 0.4 | 2.75 |
| Anorexia Nervosa | 0.8 | -0.8 | |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 0.6 | 1.1 | -0.83 |
| Atherosclerosis | 0.2 | 0.3 | -0.5 |
| Atrial fibrillation | 0.8 | 0.8 | 0 |
| Autism | 2.2 | 2.8 | -0.27 |
| Bipolar Disorder | 0 | 0.2 | 0 |
| Brain Trauma | 0.2 | 0.1 | 1 |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.5 | 0.4 | 0.25 |
| Cerebral Palsy | 0.2 | 0.1 | 1 |
| Chronic Fatigue Syndrome | 1 | 0.4 | 1.5 |
| Chronic Kidney Disease | 0.4 | 1.4 | -2.5 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | -0.2 | |
| Chronic Urticaria (Hives) | 0.5 | 1.1 | -1.2 |
| Coagulation / Micro clot triggering bacteria | 1 | 0.1 | 9 |
| Colorectal Cancer | 0.7 | 0.7 | 0 |
| Constipation | 0.1 | 0.1 | 0 |
| Coronary artery disease | 1 | 0.1 | 9 |
| COVID-19 | 1.6 | 3.6 | -1.25 |
| Crohn's Disease | 1.5 | 1.9 | -0.27 |
| cystic fibrosis | 0.5 | 0.1 | 4 |
| deep vein thrombosis | 1 | 0.1 | 9 |
| Depression | 1.8 | 3.7 | -1.06 |
| Dermatomyositis | 0 | 0 | |
| Eczema | 0.3 | 0.1 | 2 |
| Endometriosis | 0.7 | 0.1 | 6 |
| Epilepsy | 0.5 | 0.6 | -0.2 |
| Fibromyalgia | 0.2 | 0.9 | -3.5 |
| Functional constipation / chronic idiopathic constipation | 1.4 | 0.9 | 0.56 |
| gallstone disease (gsd) | 0.1 | 0.1 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.1 | 0 |
| Generalized anxiety disorder | 0.9 | 0.2 | 3.5 |
| Gout | 0.1 | -0.1 | |
| Graves' disease | 0.2 | 0.3 | -0.5 |
| Halitosis | 0 | 0 | |
| Hashimoto's thyroiditis | 0.3 | 0.1 | 2 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.7 | 0.71 |
| hypercholesterolemia (High Cholesterol) | 0.3 | -0.3 | |
| hyperglycemia | 0.6 | -0.6 | |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.2 | 1 |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.4 | 0.5 | -0.25 |
| Hypothyroidism | 0.2 | -0.2 | |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 1.3 | -1.3 | |
| Inflammatory Bowel Disease | 1.2 | 3.6 | -2 |
| Insomnia | 0.1 | 0.2 | -1 |
| Intelligence | 0.1 | 0.7 | -6 |
| Intracranial aneurysms | 0.1 | 0.2 | -1 |
| Irritable Bowel Syndrome | 0.9 | 0.5 | 0.8 |
| Liver Cirrhosis | 0.9 | 0.3 | 2 |
| Long COVID | 1.6 | 1.8 | -0.13 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0.4 | -0.4 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.5 | 0.1 | 4 |
| Menopause | 0 | 0 | |
| Metabolic Syndrome | 1.8 | 0.8 | 1.25 |
| Mood Disorders | 2.3 | 3.7 | -0.61 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.1 | 1 |
| Multiple Sclerosis | 0.7 | 2 | -1.86 |
| Multiple system atrophy (MSA) | 0.5 | 0.1 | 4 |
| Neuropathy (all types) | 0.2 | 0.2 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 1.8 | -1 |
| NonCeliac Gluten Sensitivity | 0 | 0 | |
| Obesity | 1.2 | 1.6 | -0.33 |
| obsessive-compulsive disorder | 1.1 | 2 | -0.82 |
| Osteoarthritis | 0.4 | 0.4 | |
| Osteoporosis | 0.1 | 0.4 | -3 |
| Parkinson's Disease | 1.3 | 1 | 0.3 |
| Polycystic ovary syndrome | 0.1 | 0.2 | -1 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.2 | -0.2 | |
| Psoriasis | 1.7 | 1.2 | 0.42 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 0.4 | 4.25 |
| Rosacea | 0 | 0.1 | 0 |
| Schizophrenia | 0.8 | 0.2 | 3 |
| scoliosis | 0.1 | 0.2 | -1 |
| Sjögren syndrome | 0.8 | 0.6 | 0.33 |
| Sleep Apnea | 0.1 | 0.2 | -1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0 | 0 |
| Stress / posttraumatic stress disorder | 0.8 | 0.7 | 0.14 |
| Systemic Lupus Erythematosus | 0.5 | 0.3 | 0.67 |
| Tic Disorder | 0.9 | -0.9 | |
| Tourette syndrome | 0.2 | 0 | 0 |
| Type 1 Diabetes | 0.2 | 0.2 | 0 |
| Type 2 Diabetes | 1.8 | 1.3 | 0.38 |
| Ulcerative colitis | 1 | 1.4 | -0.4 |
| Unhealthy Ageing | 0.8 | 1.3 | -0.63 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.